Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of T101 in Chronic Hepatitis B
NCT04168333Phase 1Completed
- Sponsor
- Tasly Group
- Start
- Jan 2018
- Primary completion
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing T101 Group with Placebo Group (2 arms). Primary endpoints: Adverse events at 1 year, Vital signs index at Day 99 and 4 more. Started Jan 2018; status: completed.
02
Drugs
T101
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04168333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04168333.